FDA Approves Nivolumab for Bladder Cancer

Anne Li                                                                                               March 4th, 2017


On February 2, the Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer. This makes nivolumab the second immune checkpoint inhibitor to be approved for the treatment of bladder cancer. Approximately half of patients with bladder cancer do not respond to their initial, or first-line, therapy, and only 10%–15% of those patients respond to second-line chemotherapy. The nivolumab approval is for patients with locally advanced or metastatic bladder cancer whose disease has gotten worse during or after first-line, adjuvant or neoadjuvant therapy with platinum-containing chemotherapy.


See original article at: https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-nivolumab-bladder

Post a comment